BioWorld

July 21, 2006

View Archived Issues

Gilead Buying Rest Of Corus; $365M Plus Lawsuit Payout

Just more than three months after pumping $25 million into Corus Pharma Inc., Gilead Sciences Inc. - already Corus' largest shareholder - is exercising its option to buy out the firm, at a price tag of $365 million. (BioWorld Today) Read More

ImClone Amending Erbitux Merck KGaA Arrangement

Read More

Surprise Findings On Telomere Protection Genes, Mechanisms

Read More

Cubist Backs Off HepeX-B Due To Regulatory Issues

Read More

Clinic Roundup

Read More

Other News To Note

Read More

Appointments And Advancements

Read More